From Seekingalpha · Stephen Ayers · · 40s
Parabilis Foundation Gives Free Oncology Pipeline
Rare-disease foundation PBLS shares $1B+ oncology pipeline with Regeneron.
In brief
Rare-disease foundation PBLS shares $1B+ oncology pipeline with Regeneron. Parabilis Medicines leaves $1.1B oncology pipeline free for investors after IPO. Originally reported by Seekingalpha.
Parabilis Medicines Overview
Parabilis Medicines, Inc. (PBLS) IPO'd in June 2026 after surging to $42 in September.
Investor Benefits
PBLS offers $1.1B cash, $125M Regeneron partnership, and cash runway into 2030.
Lead Asset Efficacy
Zolucatetide shows robust early efficacy in desmoid tumors and craniopharyngioma.
Market Position
PBLS trades at ~$24 with $3B market cap after 40% pullback from peak.
Here's the gist
Parabilis Medicines leaves $1.1B oncology pipeline free for investors after IPO.
